t
CVS Group plc purchased 44,368 of its ordinary shares from Peel Hunt LLP between 24 August 2026 and 28 August 2026 at a volume weighted average price of 1,299.20 GBp per share. CVS intends to cancel these purchased shares, which will result in 67,970,390 Ordinary Shares in issue and total voting rights. Since the share buyback programme commenced on 26 May 2026, a total of 2,192,709 Ordinary Shares have been repurchased at a weighted average price of 1,249.0 pence per share.
| Date | 1 Sept 2026 |
| Time | 07:00:10 |
| Category | Capital structure |
| ID | 6699S |
01 September 2026
CVS GROUP plc
("CVS" or the "Company" and, together with its subsidiaries, the "Group")
Transaction in Own Shares and Total Voting Rights
CVS announces that it purchased the following number of its ordinary shares of 0.2 pence each (“Ordinary Shares”) from Peel Hunt LLP ("Peel Hunt"), in accordance with the terms of the share buyback programme announced on 26 May 2026 (the "Share Buyback Programme").
|
Date of purchases: |
24 August 2026 - 28 August 2026 |
|
Aggregate number of Ordinary Shares purchased: |
44,368 |
|
Lowest price paid per share (GBp): |
1,290.00 |
|
Highest price paid per share (GBp): |
1,304.00 |
|
Volume weighted average price paid per share (GBp): |
1,299.20 |
CVS intends to cancel all of the purchased Ordinary Shares.
Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 67,970,390 Ordinary Shares in issue and holds no Ordinary Shares in treasury.
The total number of voting rights in CVS is therefore 67,970,390 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.
Since the commencement of the Share Buyback Programme, the Company has repurchased 2,192,709 Ordinary Shares in aggregate at a weighted average price of 1,249.0 pence per share.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, a full breakdown of the individual trades made by Peel Hunt as part of the Share Buyback Programme is attached to this announcement. http://www.rns-pdf.londonstockexchange.com/rns/6699S_1-2026-8-28.pdf
Contacts
|
CVS Group plc |
via FGS Global |
|
Richard Fairman, Chief Executive Officer |
|
|
Robin Alfonso, Chief Financial Officer |
|
|
Paul Higgs, Chief Veterinary Officer |
|
|
Charlotte Page, Head of Investor Relations |
|
|
|
|
|
FGS Global |
+44 (0)207 251 3801 |
|
Faeth Birch |
|
|
Charlie Chichester |
|
About CVS Group plc (www.cvsukltd.co.uk)
CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.
The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business("Animed Direct").
The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.